1. Home
  2. SWX vs TGTX Comparison

SWX vs TGTX Comparison

Compare SWX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southwest Gas Holdings Inc. (DE)

SWX

Southwest Gas Holdings Inc. (DE)

HOLD

Current Price

$91.71

Market Cap

6.7B

Sector

Utilities

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$50.26

Market Cap

7.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SWX
TGTX
Founded
1931
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
7.5B
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
SWX
TGTX
Price
$91.71
$50.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$87.40
$49.80
AVG Volume (30 Days)
443.5K
2.1M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
2.70%
N/A
EPS Growth
120.29
1746.67
EPS
2.49
0.17
Revenue
$5,433,972,000.00
$2,785,000.00
Revenue This Year
$18.48
$49.08
Revenue Next Year
$2.61
$26.69
P/E Ratio
$36.65
$289.88
Revenue Growth
9.56
N/A
52 Week Low
$75.75
$26.76
52 Week High
$94.47
$59.30

Technical Indicators

Market Signals
Indicator
SWX
TGTX
Relative Strength Index (RSI) 52.69 45.80
Support Level $87.53 $45.37
Resistance Level $94.11 $58.08
Average True Range (ATR) 1.66 2.01
MACD 0.01 -0.23
Stochastic Oscillator 73.64 48.41

Price Performance

Historical Comparison
SWX
TGTX

About SWX Southwest Gas Holdings Inc. (DE)

Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: